Oscotec "Value-Up Targets Achieved Ahead of Schedule... Two Licensing Deals, Return to Profitability"
"Completed 40% of the target of five technology licensing deals by 2034"
"Pursuing governance improvements, including increasing the proportion of independent directors and strengthening ESG disclosures"
Oscotec said on November 5 that it had achieved key targets in its corporate value enhancement (Value-Up) plan ahead of schedule, including two technology licensing deals and a return to profitability.
Oscotec disclosed the implementation status of its corporate value enhancement plan, announced in February 2025, on November 5. The related filing detailed the company’s research and development (R&D) results and progress toward its financial targets, and added corporate governance, environmental and social matters, and governance (ESG) as new target areas.
In R&D, the drug-resistant cancer candidate OCT-598 entered Phase 1 clinical trials in December 2025. Oscotec completed two technology licensing deals: it licensed ADEL-Y01, a candidate treatment for Alzheimer’s disease, to Sanofi in December 2025, followed by cevidoplenib, a candidate treatment for autoimmune diseases, to Agios in the United States in June 2026. This fulfills 40% of the company’s mid- to long-term target of completing at least five licensing deals by 2034.
In finance, Oscotec returned to profitability in 2025, achieving its target of turning return on equity (ROE) positive two years ahead of schedule. Consolidated ROE improved from -1.4% in 2024 to 34.1% in 2025. On a standalone basis, accumulated losses also fell by about 80%, from 100.7 billion won at the end of 2024 to 20.4 billion won at the end of June 2026.
Oscotec plans to pursue shareholder returns in stages, including cash and in-kind dividends, taking into account its available distributable profits, financial stability, and future R&D investment plans.
In corporate governance and ESG, Oscotec plans to increase the proportion of independent directors from the current 28.6% to at least one-third by its 2027 annual general meeting. The company published its ESG management policies and an ESG factbook in September 2026 and joined the United Nations Global Compact (UNGC) in October 2026. It is also working to publish its first sustainability report in the first half of 2027.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Sang-hyun, CEO of Oscotec, said, "We achieved some of the key targets set out in our initial corporate value enhancement plan, including two global technology licensing deals and a return to profitability, faster than expected. We will strengthen the competitiveness of our pipeline through continued R&D investment and pursue shareholder returns in stages in line with our financial position."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.